AMEVIVE® Pregnancy Registry

Pregnancy Clinical Trial

Official title:

Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00342862
• Other study ID #: 0485-CL-0002
• Secondary ID: C-739
• Status: Terminated
• Phase: N/A
• First received: June 19, 2006
• Last updated: December 10, 2013
• Start date: December 2003
• Est. completion date: December 2011

Study information

• Verified date: December 2013
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE® in order to detect any potential increase in the risk of major birth defects.

The AMEVIVE® Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).

Description:

Prospective reports will be collected from pregnant subjects, health care provider (HCP), or Astellas Product Safety Management staff. Data from the pregnant subjects will be collected at 4 to 5 months of pregnancy by telephone interviews with the Registry. The Registry will also contact the subject at 2 months and 12 months after the estimated delivery date (EDD) for post-natal & pediatric follow-up. The Registry will confirm the information collected from the subject with the HCP by telephone interviews with the Registry, forms mailed/faxed to the Registry, electronic forms/queries sent to the Registry, or a combination of these methods. If a live birth is reported, the infant's HCP will be contacted for the Pediatric Follow-Up at 2 months and 12 months of age. If a birth defect is reported, targeted follow-up will be conducted.

Other known NCT identifiers

• NCT00168675

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Have been exposed to AMEVIVE® within 8 weeks prior to conception or at any time during pregnancy

• Provide sufficient information to determine that the pregnancy is prospectively registered (i.e., the outcome of pregnancy must be unknown prospectively)

• Provide verbal consent to participate in the Registry, and

• Verbally provide the contact information for herself, her healthcare provider (HCP), and the infant's HCP (if applicable)

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Pregnancy

Intervention

Drug:
• Amevive exposure
Observational

Locations

Country	Name	City	State
United States	INC Research	Wilmington	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate pattern or increase in major birth defects in children of women w/ psoriasis who were exposed to AMEVIVE® at any time within the 8 wks prior to conception, or at any time during pregnancy, where outcome of the pregnancy is unknown prospectively		At month 4 to 5 of pregnancy; At 2 months and 12 months post estimated delivery date	No
Secondary	To evaluate the number of live born infants versus fetal loss in pregnant women exposed to AMEVIVE®		At 2 months post estimated delivery date	No
Secondary	To evaluate gestational age, body weight, gender, head circumference, and body length in live born infants exposed to AMEVIVE®		At 2 months post estimated delivery date	No
Secondary	To evaluate appearance, pulse, grimace, activity, and respiration (APGAR) scores at 1 and 5 minutes of age in live born infants exposed to AMEVIVE®		At 2 months post estimated delivery date	No
Secondary	To evaluate hospitalizations for infection in live born infants exposed to AMEVIVE®		At 2 months and 12 months post estimated delivery date	No
Secondary	To evaluate clinically significant infections with unusual organisms, not requiring hospitalization in live born infants exposed to AMEVIVE®		At 2 months and 12 months post estimated delivery date	No
Secondary	To evaluate malignancies in live born infants exposed to AMEVIVE®		At 2 months and 12 months post estimated delivery date	No

External Links

•   Link to Results on JAPIC